ClinicalTrials.gg
Drug

CB-839 clinical trials

Also written CB-839 and telaglenastat.

studies test it
17
open now
2
in phase 3
0
first study started
2014

How each study uses CB-839 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the CB-839 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Glutaminase inhibitor
3

Development codes

CB-839
13

Other names

telaglenastat
10

Studies by the year they started

17 studies that test it; most in 2014 (3)

Studies that test CB-839, by start year
YearStudies
20143
20163
20173
20181
20192
20202
20211
20262

Who runs them

Industry 12 · Other 5

Calithera Biosciences, Inc (12) · David Bajor, MD (1) · M.D. Anderson Cancer Center (1) · Chan, Stephen, MD, PhD (1) · Washington University School of Medicine (1) · Massachusetts General Hospital (1)

Studies

Open first, then newest update. How each study uses CB-839 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 1 — CB-839 is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Stopped1

Codes

What other systems call CB-839 · ClinicalTrials.gg INT000127

  • UNII (FDA) U6CL98GLP4TELAGLENASTATConfirmed FDA, Wikidata
  • Wikidata Q27075751CB-839Confirmed FDA, Wikidata
  • DrugBank DB15232One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.